血必净注射液联合TACE治疗原发性肝癌的临床疗效观察

目的:观察血必净注射液联合经导管肝动脉化疗栓塞术(TACE)治疗原发性肝癌的临床疗效。方法:将92例原发性肝癌患者随机分为联合组(n=47)和对照组(n=45)。对照组接受常规TACE治疗(碘油栓塞+局部化疗+对症治疗等),联合组在接受常规TACE治疗的基础上加用血必净注射液50mL+0.9%氯化钠注射液100mL,静脉滴注,每天1次,连用7d。监测患者的体温,肝、肾功能,血常规与甲胎蛋白含量变化情况,比较2组的近期疗效和急性毒性反应的差异。结果:联合组与对照组甲胎蛋白含量均较治疗前显著下降(P<0.05)。联合组和对照组总有效率分别为91.49%和88.49%,差异无统计学意义(P>0.05)。联合组的恶心、呕吐、腹痛等并发症发生率较对照组显著降低(P<0.05)。联合组的发热、肝肾功能损害和骨髓抑制等毒性反应改善情况显著优于对照组(P<0.05)。结论:血必净注射液能明显降低原发性肝癌患者行TACE后的相关毒性反应,改善患者的生存质量。

Clinical Observation of Xuebijing Injection Combined with TACE on Primary Liver Cancer

OBJECTIVE： To investigate the clinical efficacy of Xuebijing injection combined with TACE on primary liver can- cer. METHODS： 92 patients with primary liver cancer were randomly divided into combination group （n=47） and control group （n=45）. Control group was given conventional TACE treatment （iodipin embolization＋local chemotherapy＋ symptomatic treat- ment）, and combination group was additionally given Xuebijing injection 50 mL added in 0.9% Sodium chloride injection 100mL once a day for consecutive 7 days on the basis of TACE treatment. Changes of body temperature, liver and renal function, blood routine tests and AFP were all detected, and short-term efficacy and acute toxicity reaction were compared between 2 groups. RE- SULTS： Compared with before treatment, AFPs in combination group and control group were both decreased significantly （P〈 0.05）. The total effective rates were 91.49% and 88.49% in 2 groups, there was no significant difference between them （P〉0.05）. The incidence of complications such as nausea, vomit and abdominal pain in combination group were significantly lower than in control group （P〈0.05）. The improvement of toxicity such as fever, lesion of liver and kidney function and bone marrow suppres- sion were significantly better than those in control group （P〈0.05）. CONCLUSION： Xuebijing injection can reduce the related tox- icity in patients with primary liver cancer treated by TACE obviously and improve the quality of life.